RATIONALE: Hypothalamic-pituitary-adrenal (HPA) axis dysfunction is a frequent finding in psychiatric disorders, including psychotic depression and schizophrenia. Conflicting results exist concerning the influence of antipsychotics on the HPA-axis. OBJECTIVE: Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the effect of quetiapine on nocturnal urinary cortisol and melatonin excretion in 13 healthy male subjects under conditions of undisturbed and experimentally disturbed sleep. METHODS: Volunteers were studied 3 times for 3 consecutive nights (N0, adaptation; N1, standard sleep conditions; N2, acoustic stress) 4 days apart. Placebo, quetiapine 25 mg or quetiapine 100 mg was administered orally 1 h before bedtime on nights 1 and 2. Urine produced during the 8-h bedtime period was collected for later determination of cortisol and melatonin concentrations by standard radioimmunoassays. RESULTS: MANOVA showed a significant effect for N1 vs. N2 with elevated total amount of cortisol ( p<0.005) and melatonin ( p<0.05) excretion after acoustic stress. Both quetiapine 25 mg and 100 mg significantly ( p<0.0005) reduced the total amount of cortisol excretion in comparison to placebo. No interaction effect of stress condition was observed. There was no effect of quetiapine on melatonin levels. CONCLUSION: The significant reduction of nocturnal cortisol excretion following quetiapine reflects a decreased activity of the HPA-axis in healthy subjects. This finding may be an important aspect in quetiapine's mode of action in different patient populations.
RCT Entities:
RATIONALE: Hypothalamic-pituitary-adrenal (HPA) axis dysfunction is a frequent finding in psychiatric disorders, including psychotic depression and schizophrenia. Conflicting results exist concerning the influence of antipsychotics on the HPA-axis. OBJECTIVE: Therefore, this double-blind, placebo-controlled, randomized cross-over study investigated the effect of quetiapine on nocturnal urinary cortisol and melatonin excretion in 13 healthy male subjects under conditions of undisturbed and experimentally disturbed sleep. METHODS: Volunteers were studied 3 times for 3 consecutive nights (N0, adaptation; N1, standard sleep conditions; N2, acoustic stress) 4 days apart. Placebo, quetiapine 25 mg or quetiapine 100 mg was administered orally 1 h before bedtime on nights 1 and 2. Urine produced during the 8-h bedtime period was collected for later determination of cortisol and melatonin concentrations by standard radioimmunoassays. RESULTS: MANOVA showed a significant effect for N1 vs. N2 with elevated total amount of cortisol ( p<0.005) and melatonin ( p<0.05) excretion after acoustic stress. Both quetiapine 25 mg and 100 mg significantly ( p<0.0005) reduced the total amount of cortisol excretion in comparison to placebo. No interaction effect of stress condition was observed. There was no effect of quetiapine on melatonin levels. CONCLUSION: The significant reduction of nocturnal cortisol excretion following quetiapine reflects a decreased activity of the HPA-axis in healthy subjects. This finding may be an important aspect in quetiapine's mode of action in different patient populations.
Authors: G Laakmann; M Wittmann; H W Schoen; K Zygan; A Weiss; R Meissner; O A Mueller; G K Stalla Journal: Psychoneuroendocrinology Date: 1986 Impact factor: 4.905
Authors: Walid Abi-Saab; John P Seibyl; D Cyril D'Souza; Laurence P Karper; Ralitza Gueorgueva; Anissa Abi-Dargham; Ma-Li Wong; Sachin Rajhans; Joseph P Erdos; George R Heninger; Dennis S Charney; John H Krystal Journal: Psychopharmacology (Berl) Date: 2002-04-05 Impact factor: 4.530
Authors: J I Nurnberger; S Simmons-Alling; L Kessler; S Jimerson; J Schreiber; E Hollander; C A Tamminga; N S Nadi; D S Goldstein; E S Gershon Journal: Psychopharmacology (Berl) Date: 1984 Impact factor: 4.530
Authors: Stefan Cohrs; Cornelia Röher; Wolfgang Jordan; Andreas Meier; Gerald Huether; Wolfgang Wuttke; Eckart Rüther; Andrea Rodenbeck Journal: Psychopharmacology (Berl) Date: 2006-01-24 Impact factor: 4.530
Authors: Leah H Rubin; Gretchen L Haas; Matcheri S Keshavan; John A Sweeney; Pauline M Maki Journal: Neuropsychopharmacology Date: 2007-03-28 Impact factor: 7.853